ATLANTA, GA – – (July 30, 2018) – – Holzer & Holzer, LLC announces that it has filed a class action lawsuit on behalf of investors who purchased Tetraphase Pharmaceuticals, Inc. (“Tetraphase” or the “Company”) (NASDAQ: TTPH) common stock between March 8, 2017 and February 13, 2018. The lawsuit alleges that Tetraphase and other defendants made materially false and misleading statements and failed to disclose that: (i) Tetraphase was increasing the patient enrollment in its IGNITE3 trial from 1,000 patients to 1,200 patients to meet the trial’s primary endpoints (within the 10% non-inferiority margin); (ii) the enrollment of more patients in the trial indicated that the existing population was inadequate to meet the trial’s primary endpoints; and (iii) as a result, Tetraphase’s public statements were materially false and misleading at all relevant times. If you purchased Tetraphase common stock between March 8, 2017 and February 13, 2018 and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer Esq. at firstname.lastname@example.org or Alexandria P. Rankin, Esq. at email@example.com, or call the firm by toll-free telephone at (888) 508-6832. The deadline to ask the court to be appointed lead plaintiff is September 25, 2018.